P
Peter A. Prieto
Researcher at University of Rochester Medical Center
Publications - 45
Citations - 6032
Peter A. Prieto is an academic researcher from University of Rochester Medical Center. The author has contributed to research in topics: Melanoma & Immune checkpoint. The author has an hindex of 16, co-authored 40 publications receiving 4164 citations. Previous affiliations of Peter A. Prieto include University of Texas MD Anderson Cancer Center & Yale University.
Papers
More filters
Journal ArticleDOI
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
Vancheswaran Gopalakrishnan,Vancheswaran Gopalakrishnan,Christine N. Spencer,Christine N. Spencer,Luigi Nezi,Alexandre Reuben,Miles C. Andrews,Tatiana Karpinets,Peter A. Prieto,D. Vicente,K. Hoffman,Spencer C. Wei,Alexandria P. Cogdill,Li Zhao,Courtney W. Hudgens,Diane S. Hutchinson,T. Manzo,M. Petaccia de Macedo,Tiziana Cotechini,T. Kumar,Wei Shen Chen,Sangeetha M. Reddy,R. Szczepaniak Sloane,Jessica Galloway-Peña,Hong Jiang,P. L. Chen,Elizabeth J. Shpall,Katayoun Rezvani,Amin M. Alousi,Roy F. Chemaly,Samuel A. Shelburne,Luis M Vence,Pablo C. Okhuysen,V. B. Jensen,Alton G. Swennes,Florencia McAllister,E. Marcelo Riquelme Sanchez,Yu Zhang,Laurence Zitvogel,Nicolas Pons,Jacob Austin-Breneman,Lauren E. Haydu,Elizabeth M. Burton,J. M. Gardner,E. Sirmans,Jing Shan Hu,Alexander J. Lazar,Takahiro Tsujikawa,Adi Diab,Hussein Abdul-Hassan Tawbi,Isabella C. Glitza,Wen-Jen Hwu,Sapna Pradyuman Patel,Scott E. Woodman,Rodabe N. Amaria,Michael A. Davies,Jeffrey E. Gershenwald,Patrick Hwu,J. E. Lee,Jianhua Zhang,Lisa M. Coussens,Zachary A. Cooper,P.A. Futreal,Carrie R. Daniel,Carrie R. Daniel,Nadim J. Ajami,Joseph F. Petrosino,Michael T. Tetzlaff,Pradeep Sharma,James P. Allison,Robert R. Jenq,Jennifer A. Wargo +71 more
TL;DR: Examination of the oral and gut microbiome of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy suggested enhanced systemic and antitumor immunity in responding patients with a favorable gut microbiome as well as in germ-free mice receiving fecal transplants from responding patients.
Journal ArticleDOI
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Pei Ling Chen,Whijae Roh,Alexandre Reuben,Zachary A. Cooper,Christine N. Spencer,Peter A. Prieto,John P. Miller,Roland L. Bassett,Vancheswaran Gopalakrishnan,Khalida Wani,Mariana Petaccia de Macedo,Jacob Austin-Breneman,Hong Jiang,Qing Chang,Sangeetha M. Reddy,Wei Shen Chen,Michael T. Tetzlaff,Russell J. Broaddus,Michael A. Davies,Jeffrey E. Gershenwald,Lauren E. Haydu,Alexander J. Lazar,Sapna Pradyuman Patel,Patrick Hwu,Wen-Jen Hwu,Adi Diab,Isabella C. Glitza,Scott E. Woodman,Luis M Vence,Ignacio I. Wistuba,Rodabe N. Amaria,Lawrence N. Kwong,Victor G. Prieto,R. Eric Davis,Wencai Ma,Willem W. Overwijk,Arlene H. Sharpe,Jianhua Hu,P. Andrew Futreal,Jorge Blando,Padmanee Sharma,James P. Allison,Lynda Chin,Jennifer A. Wargo +43 more
TL;DR: It is demonstrated that adaptive immune signatures in tumor biopsy samples obtained early during the course of treatment are highly predictive of response to immune checkpoint blockade and also demonstrate differential effects on the tumor microenvironment induced by CTLA4 and PD-1 blockade.
Journal ArticleDOI
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh,Pei Ling Chen,Alexandre Reuben,Christine N. Spencer,Peter A. Prieto,John P. Miller,Vancheswaran Gopalakrishnan,Feng Wang,Zachary A. Cooper,Sangeetha M. Reddy,Curtis Gumbs,Latasha Little,Qing Chang,Wei Shen Chen,Khalida Wani,Mariana Petaccia de Macedo,Eveline Chen,Jacob Austin-Breneman,Hong Jiang,Jason Roszik,Michael T. Tetzlaff,Michael A. Davies,Jeffrey E. Gershenwald,Hussein Abdul-Hassan Tawbi,Alexander J. Lazar,Patrick Hwu,Wen-Jen Hwu,Adi Diab,Isabella C. Glitza,Sapna Pradyuman Patel,Scott E. Woodman,Rodabe N. Amaria,Victor G. Prieto,Jianhua Hu,Padmanee Sharma,James P. Allison,Lynda Chin,Jianhua Zhang,Jennifer A. Wargo,P. Andrew Futreal +39 more
TL;DR: Deep molecular profiling of melanoma patients treated with sequential checkpoint blockade demonstrated that a more clonal T cell repertoire was predictive of response to PD-1 but not CTLA-4 blockade, suggesting the potential utility of a combinatorial biomarker to optimize patient care with checkpoint blockade therapy.
Journal ArticleDOI
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Peter A. Prieto,James Chih-Hsin Yang,Richard M. Sherry,Michael S. Hughes,Udai S. Kammula,Donald E. White,Catherine Levy,Steven A. Rosenberg,Giao Q. Phan +8 more
TL;DR: This report shows that ipilimumab can induce durable, potentially curative tumor regression in a small percentage of patients with metastatic melanoma and seems to have an increased CR rate, but this needs to be tested in a randomized trial.
Journal ArticleDOI
CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Mark E. Dudley,Colin A. Gross,Michelle M. Langhan,Marcos R. Garcia,Richard M. Sherry,James Chih-Hsin Yang,Giao Q. Phan,Udai S. Kammula,Michael S. Hughes,Deborah Citrin,Nicholas P. Restifo,John R. Wunderlich,Peter A. Prieto,Jenny J. Hong,Russell C. Langan,Daniel Zlott,Kathleen E. Morton,Donald E. White,Carolyn M. Laurencot,Steven A. Rosenberg +19 more
TL;DR: This study shows that a rapid and simplified method can be used to reliably generate CD8+ enriched young TIL for administration as an individualized therapy for advanced melanoma, and may allow this potentially effective treatment to be applied at other institutions and to reach additional patients.